ELEKTA HAS RECEIVED APPROVAL FOR ELEKTA COMPACT™ IN CHINA

ELEKTA HAS RECEIVED APPROVAL FOR ELEKTA COMPACT™ IN CHINA

Press Release 
Stockholm, Sweden, January 12, 2009

Elekta has received approval from the Chinese authority SFDA (State Food and
Drug Administration) to sell its linear accelerator Elekta Compact™ in China.


Elekta Compact™ is a competitive linear accelerator for high quality
conventional radiotherapy, configured for countries in need of rapid build-up of
additional treatment capacity. Elekta Compact is based on a combination of
technology from Elekta and from the product platform developed by the Chinese
company BMEI, which Elekta acquired in 2006. 

− There is a large potential for Elekta Compact in China, where there is
shortage of good cancer treatment. The number of linear accelerators is less
than one per million inhabitants and a large part of the existing systems needs
to be replaced. Further, Elekta Compact is the ideal treatment system when
replacing existing Cobalt units as the platform allows for further growth and
expansion, says Tomas Puusepp, President and CEO of Elekta. 
In May 2008 Elekta received SFDA approval to export Elekta Compact outside China
and in June 2008 Elekta completed the process of adding CE marking, allowing
Elekta Compact to be marketed in Europe, Latin America and Asia.


For further information, please contact:

Lena Schattauer, Investor Relations, Elekta AB
Tel: +46 8 587 257 22, +46 70 595 51 00, e-mail: lena.schattauer@elekta.com   


About Elekta

Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated state of the art tools and treatment planning systems for
radiation therapy and radiosurgery, as well as workflow enhancing software
systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and
resource-efficient solutions that offer confidence to both healthcare providers
and patients, Elekta aims to improve, prolong and even save patient lives,
making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000
hospitals globally, and every day more than 100,000 patients receive diagnosis,
treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is
located in Stockholm, Sweden, and the company is listed on the Nordic Exchange
under the ticker EKTAb. For more information about Elekta, please visit
www.elekta.com.